Anton Gopka is a Managing Partner at ATEM Capital with a primary focus on private investments. Before ATEM, Mr. Gopka was managing a biotechnological venture capital fund — a US$760 million strategic partnership between Domain Associates and a sovereign technology fund. Anton was responsible for eleven private investments into high-profile US biotech development companies and managed public offerings of four companies on NASDAQ.

Before that, Mr. Gopka held senior positions in M&A advisory at Barclays Capital, Sistema JSFC (LSE: SSA), and Dresdner Kleinwort. Previous board memberships include Atea Pharmaceuticals (NASDAQ: AVIR), Marinus Pharmaceuticals (NASDAQ: MRNS), Tobira Therapeutics (NASDAQ: TBRA), and Miramar Labs (observer). Mr. Gopka received a master's degree in international economics from the Moscow State University for International Affairs (MGIMO-University), an advanced corporate finance course diploma from INSEAD, and a Board Leadership certificate from Harvard Business School.

He is a member of the US National Association of Corporate Directors (NACD) and a member of the Review Committee of the National Cancer Institute (NCI).

Elena Maley is a Managing Partner at ATEM Capital. She has over ten years of successful investment experience in venture capital and private equity. Before ATEM, Elena was a partner at an investment firm that managed a US$0.75 billion investment partnership between Domain Associates, a US life sciences venture capital, and a sovereign high-tech fund. Also, Elena was on the board of directors of Syndax Pharmaceuticals (NASDAQ: SNDX), an immuno-oncology company. Elena studied Advanced Portfolio Management and Finance at York University, Board Leadership at Harvard Business School, and Business Law at UCSD.

Ilia Ardabevskii is a Principal at ATEM Capital. Ilia is a skilled investment analyst with over 5 years of experience in the finance and investment industry. He has expertise in creating executive summaries, conducting market research, performing due diligence, and contributing to the closing of multi-million dollar investment deals. During his time at ATEM Capital as a part-time Investment Analyst and currently as a Principal, he created executive summaries, info memos, and other required documents on over 50 life sciences companies, and participated in due diligence for 3 investment deals worth $30M.

Yulii Bogatyrenko is a Venture Partner at ATEM Capital with extensive global markets expertise. Mr. Bogatyrenko has over 20 years of General Management and Business Development experience in Biopharma and Healthcare in the U.S., Europe, Latin America, and the Asia Pacific.

He is the Principal of Biopharma C&I, a biotechnology consulting firm that works with smaller private and public biotech companies in Business Development and Partnering, Financing, Commercialization and Launch Readiness and R&D Strategy. Prior to that Yulii held leadership positions in Commercial and Business Development organizations and led led large commercial franchises at Bayer, Pfizer/Wyeth and Teva Specialty business.

He successfully managed over 15 launches globally and built biopharma partnerships in the U.S., Europe, and the rest of the world. Yulii has significant experience across multiple therapeutic areas, including Oncology, Rare and Orphan, CNS, Inflammation, CV, Dermatology and other therapeutic areas. He started his healthcare career with Oxford Health in NYC, and A.T.Kearney in Cambridge, working with large payer organizations in the U.S. and Europe as well as biotech product launches, restructurings, and M&A.

Yulii holds an MBA in Finance from L. Stern School of Business, NYU.

Zakhar Leikin is a Medical Advisor at ATEM Capital and a Chief Medical Director at NovaMedica, a subsidiary of Domain Associates, a US venture capital firm. He has over 15 years of experience in clinical trials, drug development, and investments. Zakhar is Before that, Zakhar was a leading medical expert in a US$0.75 billion biotechnology fund and investment partnership between Domain Associates and a sovereign high-tech fund. He started his career as a practicing neurosurgeon and resident cardiothoracic surgeon in leading medical centers.

Prof. Victor Koteliansky has over 40 years of experience in Life Sciences and biotechnology R&D. Victor was the Senior VP for Science at Alnylam Pharmaceuticals, Cambridge, MA (NASDAQ: ALNY). Before Alnylam, he spent ten years at Biogen Inc., Cambridge, MA (NASDAQ: BIIB). He has a vast global network of relations with the leading scientists in the key fields: molecular biology and genetics, RNA technologies, nano-delivery platforms, genetic engineering, immune-oncology, etc.

Peter Starokadomsky is a Scientific Partner at ATEM Capital. Peter is a research scientist at UT Southwestern Medical Center, one of the premier academic medical centers in the US, integrating pioneering biomedical research with exceptional clinical care and education. The institution’s faculty includes many distinguished members, including six awarded Nobel Prizes since 1985. Peter completed his postdoctoral research at the Weismann Institute of Science (Israel). His main scientific focus is in molecular immunology, immune-oncology, and rare diseases.

Peter is also the editor of Frontiers magazine and author of 50 scientific papers in molecular biology, immunology, genetics, neurobiology, and philosophy. He discovered two rare human syndromes and a new structure of RNA complexes.

Dr. Camardo has 30 years of global biopharmaceutical experience and extensive expertise in every stage of oncology drug development. He is Head of Medical Affairs at ADC Therapeutics (NYSE: ADCT). Before ADCT, he was Senior Vice President of Celgene Global Health. Before Celgene, Dr. Camardo was Senior Vice President of Clinical Development and Medical Affairs at Forest Research Institute and spent more than 20 years at Wyeth Research before its acquisition by Pfizer. At Wyeth, he held roles including Senior Vice President of Global Medical Affairs and Senior Vice President of Clinical Research and Development. He oversaw developing the first-ever approved antibody-drug conjugate Mylotarg™ (gemtuzumab ozogamicin) for acute myeloid leukemia, among other oncology development programs.

Dr. Camardo completed medical school at the University of Pennsylvania and is board certified in internal medicine.

D. Bruce Burlington, M.D. is a prominent independent consultant on pharmaceutical product development and regulatory affairs with more than 30 years of experience in regulatory affairs and drug development with special interests in helping companies prepare for critical meetings with FDA, conduct product due to diligence evaluations, and set up processes, organizations, and staffing plans to achieve their regulatory obligations.

He is a Member of the Boards of Directors for AstraZeneca and Cangene.

Bruce Burlington’s extensive experience in drug and product development comprises several senior posts at Wyeth, including Executive Vice President and Worldwide Head of Regulatory Affairs, where he played a central role in developing and global registration of many products.

Before joining Wyeth, Bruce Burlington was a leader at the U.S. Food and Drug Administration (FDA), where he served for 17 years in various roles, including director of the Division of Biological Investigational New Drugs, several management positions in the Center for Drug Evaluation and Research, and director of the Center for Devices and Radiological Health.

As an infectious disease physician and a leader in regulatory policy, Bruce Burlington has served as the industry representative on the FDA’s Drug Safety and Risk Management Advisory Committee.

Bruce Burlington graduated from Louisiana Tech University with a B.A. in Psychology and Economics and received his M.D. degree from Louisiana State University.

He completed his internal medicine internship and residency and his infectious disease fellowship at the University of Colorado.

Ed Godber serves as a VP BioPharma Partnership at Guardant Health (NasdaqGS: GH), a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary blood tests, vast data sets, and advanced analytics. Before Guardant Health, he was Chief Business Officer and Executive Vice President of Life Science Ventures at PatientsLikeMe, a patient-powered research network. Before that, he was the Chief Executive Officer of the London-based Health Labs Advisory Boards, where he was a strategic advisor to pharma, biotech, venture capital, and nonprofit organizations.

He also spent nearly five years at GlaxoSmithKline (GSK) as Senior Vice President, heading up access to medicines as part of the European Executive Team and exploring evidence innovation within the research and development division. In that position, he also co-founded a multi-million dollar external scientific collaboration on real-world data.

Godber began his career in public health, strategic commissioning, and policy research in the UK’s National Health Service (NHS). He has advised a wide range of transformational ventures, including the Bill & Melinda Gates Foundation and the Chatham House Working Group on Anti-Bacterial Resistance.

He holds a master’s degree in health economics from the University of York and a master’s degree in business administration from the London Business School.

Rivka Kreitman is a Senior Partner at KRDable consulting, a strategic drug development, product evaluation, and partnerships consultancy. Also, she serves as a board member at the Philadelphia Israel Chamber of Commerce, a board member of the BrainBoost Innovation Center, and a member of the Scientific Advisory Board at Rerum Novarum, a Philadelphia based firm dedicated to the support of the university and corporate technology transfer and the global commercialization of innovation.

Before this, Rivka has been with Teva for 26 years, during which she has held many roles ranging from BD (sourcing of new projects). She was running pharmacological studies assessing the mechanism of action of Copaxone (a drug for Multiple Sclerosis), managing the North America IR&D function and the Global Clinical Operation, heading Branded Regulatory Affairs and the Global Innovative Research and Development (IR&D). Her focus is mainly on CNS, Autoimmune and Oncology, Biologics, Women’s health, Immunology, and Cell therapy. In one of her last roles at Teva, Rivka was responsible for leading the search for new products, scientific evaluation of all opportunities, and collaborating with partners on early-stage assets and technologies.

Rivka earned her Ph.D. at the Weizmann Institute of Science, Israel (Biochemistry) and postdoctoral work at Princeton University, NJ, US (Molecular Biology).